Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.48 |
| ▸ | HTR2A | P28223 | 10/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776144 | 0.90 | KMT2A (0.44) | ALDH1A1 | |
| SCHEMBL16776097 | 0.89 | HTR2C (0.45) | HTR2CHTR2AABL1BCR | |
| SCHEMBL16776255 | 0.88 | HTR2C (0.46) | HTR2CHTR2A | |
| SCHEMBL16776241 | 0.88 | HTR2C (0.44) | HTR2CHTR2AABL1BCR | |
| SCHEMBL16785538 | 0.88 | HTR2A (0.49) | HTR2CHTR2A | |
| SCHEMBL16775910 | 0.88 | TSHR (0.48) | HTR2CHTR2A | |
| SCHEMBL16776226 | 0.87 | HTR2C (0.45) | HTR2CHTR2AABL1BCR | |
| SCHEMBL16776011 | 0.86 | CA9 (0.38) | HTR2CHTR2AALDH1A1 | |
| SCHEMBL16776009 | 0.86 | HTR2C (0.45) | HTR2CHTR2AABL1BCR | |
| SCHEMBL16776157 | 0.85 | ROCK2 (0.36) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4651/4885HTR2A 4386/4885ABL1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.